John Klein has served as the chairman of the New Jersey-based pharmaceutical company Cambridge Therapeutics for more than seven years. Over the course of his career, he has spearheaded Federal Drug Administration (FDA) approval for over 300 generic drugs and provided strategic leadership to Cambridge Therapeutics. John Klein is also committed to staying abreast of health- and public policy-related news in New Jersey.
A June report released by the state Department of Health called for improvements to infectious-disease outbreak prevention efforts at the state’s long-term care hospitals. The statement suggested new protocols to keep visitors and staff from introducing new diseases to these facilities, create strategies to address disease outbreaks, and set guidelines to separate infected and healthy patients.
These recommendations were made in response to the 2018 viral outbreak at the Wanaque Center for Nursing and Rehabilitation, which contributed to the death of 11 people and approximately 30 new cases of illnesses. While most healthy patients with the condition would only experience mild respiratory issues, it poses a at particular risk for youths on ventilators and other daily-living devices. The medical center cared for numerous such individuals at the time.
Several of the New Jersey Department of Health’s propositions would require changes to the state’s current legislation, as well as increased funding to cover their cost. In addition to suggesting how long-term care facilities handle future outbreaks, the department is examining its guidance for medical-center plans for promptly notifying caregivers and families.